Zentalis Pharmaceuticals, INC

Zentalis Pharmaceuticals, Inc. reported the results of its 2026 Annual Meeting of Stockholders, confirming the election of two Class III directors and the ratification of its independent auditor.

Zentalis Pharmaceuticals, Inc. announced the appointment of Shannon Campbell as a Class I director, expanding the Board of Directors from six to seven members.

Zentalis Pharmaceuticals announced encouraging clinical activity for azenosertib combined with paclitaxel in platinum-resistant ovarian cancer patients.

Zentalis Pharmaceuticals has dosed the first patient in its Phase 3 ASPENOVA clinical trial evaluating azenosertib for platinum-resistant ovarian cancer, a step towards potential full approval.

Zentalis Pharmaceuticals presented new preclinical data for azenosertib in triple-negative breast cancer and real-world evidence in ovarian cancer at the 2026 AACR Annual Meeting.

Zentalis Pharmaceuticals announced the selection of 400mg QD 5:2 as the optimal monotherapy dose for azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer, advancing pivotal trials.

Zentalis Pharmaceuticals reports Q1 2026 results, with a focus on advancing azenosertib clinical trials and managing cash runway.

Zentalis Pharmaceuticals reports reduced net losses and extended cash runway into late 2027, driven by strategic restructuring and ongoing clinical development of azenosertib for ovarian cancer.

Zentalis Pharmaceuticals reports reduced net losses and extended cash runway into late 2027, driven by strategic restructuring and progress in its lead ovarian cancer drug, azenosertib.

Zentalis Pharmaceuticals announces its Q1 2025 financial results and provides an update on the clinical development of its lead drug candidate, azenosertib, focusing on Cyclin E1+ PROC.

Zentalis Pharmaceuticals reported a net loss of $118.4 million for the first nine months of 2024, while highlighting progress in its azenosertib clinical development program.

Zentalis Pharmaceuticals reports a net loss of $78.2 million for the first half of 2024, while also providing updates on its clinical programs, including a partial clinical hold on certain azenosertib trials.

Zentalis Pharmaceuticals, Inc. reported a net loss of $137.1 million for 2025, narrowing from $165.9 million in 2024, as it strategically restructured to prioritize its lead oncology candidate, azenosertib, and extend its cash runway into late 2027.

Zentalis Pharmaceuticals focuses on advancing azenosertib, a WEE1 inhibitor, for ovarian cancer treatment while managing financial resources.

Zentalis Pharmaceuticals has formalized an employment agreement with Diana Hausman, M.D., as its new Chief Medical Officer, effective January 19, 2024.

David Michael Johnson, a Director at Zentalis Pharmaceuticals, Inc., acquired 57,100 shares of common stock through a grant of restricted stock units.

Zentalis Pharmaceuticals reports a Form 4 filing detailing the acquisition of restricted stock units by Director Jan Skvarka.

Luke Walker, a Director at Zentalis Pharmaceuticals, Inc., acquired 57,100 shares of common stock through a grant of restricted stock units.

Director Enoch Kariuki of Zentalis Pharmaceuticals acquired 57,100 shares of common stock through a grant of restricted stock units.

Zentalis Pharmaceuticals, Inc. reports that Director Scott Myers received 57,100 restricted stock units under the company's Non-Employee Director Compensation Program.

Zentalis Pharmaceuticals, Inc. reports a grant of restricted stock units to Director Shannon Campbell.

Zentalis Pharmaceuticals, Inc. has filed an amendment to its definitive proxy statement to correct a typographical error regarding the membership of its Nominating and Corporate Governance Committee ahead of the June 17, 2025 Annual Meeting.

Zentalis Pharmaceuticals has filed a definitive proxy statement with the SEC, related to its upcoming shareholder meeting.

Zentalis Pharmaceuticals announces its 2025 Annual Meeting of Stockholders to be held virtually on June 17, 2025, featuring director elections, auditor ratification, and executive compensation advisory vote.

Zentalis Pharmaceuticals has appointed Dr. Luke Walker to its Board of Directors, increasing its size from six to seven members, effective May 24, 2024.

Zentalis Pharmaceuticals has filed a definitive proxy statement with the SEC, signaling upcoming shareholder actions.

Zentalis Pharmaceuticals announces its 2024 Annual Meeting of Stockholders to be held virtually on June 21, 2024, to vote on director elections, auditor ratification, and executive compensation.

Matrix Capital Management and David E. Goel have completed an exit filing, reporting zero beneficial ownership in Zentalis Pharmaceuticals after a private sale of shares.

Matrix Capital Management Company, LP reduced its stake in Zentalis Pharmaceuticals, Inc. to 9.98% through a share repurchase, coinciding with a director's resignation.

The Walters Group and its principals have increased their beneficial ownership in Zentalis Pharmaceuticals, Inc. to 19.7% of common stock.

5AM Opportunities II and Master Funds, along with managing members Andrew J. Schwab and Kush Parmar, report a combined 6.4% beneficial ownership in Zentalis Pharmaceuticals, Inc. following an at-the-market offering.

Barclays PLC has reported a 5.32% beneficial ownership stake in Zentalis Pharmaceuticals Inc., totaling 3,841,449 common shares.

Millennium Management LLC and affiliates reported a 1.3% beneficial ownership stake in Zentalis Pharmaceuticals, Inc. as of September 30, 2025.

BlackRock, Inc. has filed an amendment to its Schedule 13G, disclosing a 2.2% passive beneficial ownership stake in Zentalis Pharmaceuticals Inc. as of June 30, 2025.

Eventide Asset Management, along with Finny Kuruvilla and Robin C. John, has filed an amended Schedule 13G indicating they no longer hold any beneficial ownership in Zentalis Pharmaceuticals, Inc.